Sharemaestro company-news research for Keros Therapeutics Inc (KROS), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Measured evidence
Company news sentiment
KROS news sentiment
Keros Therapeutics Inc
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone48Neutral is 50
Balanced news tone
39/100 evidence confidence
100% direct company focus
1 current stories across 1 publishers
Current company news
Price moving ahead of tone
Balanced news tone is drawn from 1 fresh independent stories, including 1 company-specific items across 1 publishers.
Latest source headline Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts MarketBeat · 10 Aug 2026 06:42What supports the read
1 current stories are mapped specifically to KROS.
What tempers the read
Only 1 publisher currently contribute to the measured read.
Price is moving more forcefully than the current news tone suggests.
48/100
Weighted toneBalanced news tone
39/100
Evidence confidencethin evidence
100%/100
Company focus1 direct stories
N/A/100
Evidence agreementrequires at least 2 stories
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth12
1.0 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness58
recency-weighted evidenceAgreement0
requires at least 2 storiesSource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Price is moving more forcefully than the current news tone suggests.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Value support
News subjects
What is shaping the score
Analyst action451 stories · 100%
Source mix
Where the evidence comes from
MarketBeat451 stories · 100%
Recurring subjects
Subjects appearing most often
Topic structure will appear when classified tags are present in the current feed.
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#145Tone
MarketBeatDirect company coverage
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts
- Published
- 10 Aug 2026 06:42
- Catalyst
- Analyst action
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Earlier company news
KROS news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above.
Aug
02
2026
MarketBeatArchivedNeutral tone
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Zacks Research
- Published
- 2 Aug 2026 04:27
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
25
2026
TradingKeyArchivedNeutral tone
KROS|Keros Therapeutics Inc|Price:10.060|Chg%:-0.080
- Published
- 25 Jul 2026 18:43
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
25
2026
Stock TitanArchivedNeutral tone
Keros Therapeutics (NASDAQ: KROS) names interim finance and accounting head
- Published
- 25 Jul 2026 10:54
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
21
2026
Stock TitanArchivedNeutral tone
Keros Therapeutics (KROS) director adds 1,000 shares under 10b5-1 plan
- Published
- 21 Jul 2026 18:53
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
12
2026
Stock Traders DailyArchivedNeutral tone
Discipline and Rules-Based Execution in KROS Response
- Published
- 12 Jul 2026 05:37
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
10
2026
Investing.com NigeriaArchivedNeutral tone
Form 4 Keros Therapeutics Inc For: 6 July By Investing.com
- Published
- 10 Jul 2026 11:51
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
09
2026
MoomooArchivedNeutral tone
Keros Therapeutics | DEFA14A: Others
- Published
- 9 Jul 2026 06:17
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
05
2026
Stock Traders DailyArchivedNeutral tone
Behavioral Patterns of KROS and Institutional Flows
- Published
- 5 Jul 2026 00:50
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
28
2026
ZacksArchivedNeutral tone
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
- Published
- 28 Jun 2026 02:33
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
26
2026
Stock TitanArchivedNeutral tone
Keros adds former biotech CEO Anne Prener to its board July 1
- Published
- 26 Jun 2026 13:02
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
25
2026
Investing.comArchivedNeutral tone
Keros Therapeutics director Nima sells $28,166 in company stock
- Published
- 25 Jun 2026 06:19
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
22
2026
TradingKeyArchivedNeutral tone
Keros Therapeutics Inc (KROS) Valuation: PE, PB & Fair Value Analysis
- Published
- 22 Jun 2026 18:17
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.